Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain

Publication date: January 2015 Source:Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), Volume 92 Author(s): M. Lagarde , M. Hachem , N. Bernoud-Hubac , M. Picq , E. Véricel , M. Guichardant 1-acetyl,2-docosahexaenoyl-glycerophosphocholine (AceDoPC) has been made to prevent docosahexaenoyl (DHA) to move to the sn-1 position as it rapidly does when present in 1-lyso,2-docosahexaenoyl-GPC (lysoPC-DHA), an efficient DHA transporter to the brain. When incubated with human blood, AceDoPC behaves closer to lysoPC-DHA than PC-DHA in terms of binding to plasma albumin and lipoproteins, and DHA incorporation into platelets and red cells. In addition, AceDoPC prevents more efficiently the deleterious effects of the experimental stroke in rats than does unesterified DHA. Also, AceDoPC inhibits platelet-activating factor-induced human blood platelet aggregation. Overall, AceDoPC might act as an efficient DHA transporter to the brain, and as a neuro-protective agent by itself.

Source: Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) - February 2, 2015 Category: Lipidology Source Type: research